These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 17094405)

  • 1. The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients.
    Perik PJ; De Vries EG; Boomsma F; Messerschmidt J; Van Veldhuisen DJ; Sleijfer DT; Gietema JA; Van der Graaf WT
    Anticancer Res; 2006; 26(5B):3803-11. PubMed ID: 17094405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors.
    Perik PJ; Van der Graaf WT; De Vries EG; Boomsma F; Messerschmidt J; Van Veldhuisen DJ; Sleijfer DT; Gietema JA
    Acta Oncol; 2006; 45(2):175-83. PubMed ID: 16546863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
    Fürstenberger G; Senn E; Morant R; Bolliger B; Senn HJ
    Breast; 2006 Feb; 15(1):64-8. PubMed ID: 15998587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
    Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
    J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
    Bustová I
    Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
    Buijs C; Rodenhuis S; Seynaeve CM; van Hoesel QG; van der Wall E; Smit WJ; Nooij MA; Voest E; Hupperets P; TenVergert EM; van Tinteren H; Willemse PH; Mourits MJ; Aaronson NK; Post WJ; de Vries EG
    J Clin Oncol; 2007 Dec; 25(34):5403-9. PubMed ID: 18048822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer.
    Coccaro M; Gallucci G
    J Clin Oncol; 2008 Jul; 26(19):3288; author reply 3289. PubMed ID: 18591567
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
    Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
    Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors.
    Perik PJ; De Vries EG; Boomsma F; van der Graaf WT; Sleijfer DT; van Veldhuisen DJ; Gietema JA
    Anticancer Res; 2005; 25(5):3651-7. PubMed ID: 16101196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer.
    Sánchez-Suárez P; Ostrosky-Wegman P; Gallegos-Hernández F; Peñarroja-Flores R; Toledo-García J; Bravo JL; Del Castillo ER; Benítez-Bribiesca L
    Mutat Res; 2008 Apr; 640(1-2):8-15. PubMed ID: 18207203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
    Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
    Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
    Tzaida O; Gogas H; Dafni U; Kyroudi A; Papaspyrou I; Kyriakou V; Malamou-Mitsi V; Alamani M; Skopa C; Kostopoulos I; Kastritis E; Pectasides D; Briasoulis E; Kalofonos HP; Aravantinos G; Fountzilas G; Arapantoni-Dadioti P
    Oncology; 2007; 72(5-6):388-96. PubMed ID: 18187961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer.
    Schmitt M; Sweep FC
    Eur J Cancer; 2009 Sep; 45(14):2444-6. PubMed ID: 19647994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.